CAPR — Capricor Therapeutics, Inc. Stock Price, Chart & AI Report

Negative Aug 30, 2026 • 19:50 UTC GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

Kessler Topaz Meltzer & Check, LLP - INVESTOR DEADLINE ALERT: Capricor Therapeutics, Inc. (CAPR) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (CAPR) for allegedly making material misstatements regarding its lead product Deramiocel's statistical analysis plan and FDA compliance. The FDA revealed that Capricor made undisclosed changes to the pre-specified statistical analysis plan without prior FDA agreement, leading to FDA disagreement with the methodology. Following the FDA's unfavorable briefing documents on July 27, 2026, Capricor's stock price fell 64%. Investors who purchased CAPR securities between December 17, 2025 and July 26, 2026 can seek lead plaintiff status by September 28, 2026.

CAPR securities fraud class action lawsuit FDA approval Deramiocel statistical analysis plan stock decline lead plaintiff

Sentiment note

The company is accused of material misstatements and omissions regarding its lead product's statistical analysis plan and FDA compliance. The FDA disagreed with undisclosed changes to the analysis methodology, resulting in an unfavorable benefit-risk assessment. The stock declined 64% following the FDA's public disclosure of these issues, indicating significant loss of investor confidence and regulatory setback.

Negative Aug 30, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating substantial risk of regulatory rejection. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 are urged to join the lawsuit, with a lead plaintiff deadline of September 28, 2026.

CAPR class action lawsuit securities fraud Deramiocel FDA approval Biologics License Application Duchenne muscular dystrophy investor harm

Sentiment note

The company is accused of making materially false and misleading statements about its drug candidate Deramiocel and failing to disclose that it changed its statistical analysis plan without FDA agreement, creating substantial regulatory approval risk. This represents serious securities law violations and potential investor losses.

Negative Aug 30, 2026 • 01:30 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LONGSTANDING FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

A securities class action lawsuit has been filed against Capricor Therapeutics for allegedly making materially false statements regarding its Deramiocel cell therapy. The lawsuit claims the company made undisclosed changes to statistical analysis plans for clinical data and failed to obtain FDA agreement before resubmitting the Biologics License Application, creating substantial regulatory approval risks. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of September 28, 2026.

CAPR securities class action Deramiocel cell therapy FDA Biologics License Application Duchenne muscular dystrophy statistical analysis plan

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding undisclosed changes to clinical trial analysis plans and lack of FDA agreement before BLA resubmission, creating substantial regulatory risks for its lead therapeutic candidate.

Negative Aug 26, 2026 • 19:42 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics in the U.S. District Court for the Southern District of California. The complaint alleges that the company made materially false and misleading statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 can join the lawsuit, with a lead plaintiff deadline of September 28, 2026.

CAPR class action lawsuit securities fraud Deramiocel FDA approval statistical analysis plan Duchenne muscular dystrophy regulatory risk

Sentiment note

The company is the subject of a class action lawsuit alleging material misstatements and non-disclosure of critical information regarding FDA regulatory approval risks for its lead drug candidate Deramiocel. The allegations suggest deliberate or reckless concealment of adverse facts about business prospects.

Negative Aug 26, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Capricor Therapeutics alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan without FDA agreement and failed to disclose the significant risk that the FDA would reject the Biologics License Application, putting regulatory approval for treating Duchenne muscular dystrophy in jeopardy.

CAPR class action lawsuit securities fraud Deramiocel FDA approval Biologics License Application Duchenne muscular dystrophy statistical analysis plan

Sentiment note

The company is accused of making materially false and misleading statements about its drug candidate and failing to disclose significant regulatory risks. The allegations suggest potential FDA rejection of its BLA, which poses a substantial threat to the company's business prospects and investor value.

Negative Aug 26, 2026 • 13:45 UTC GlobeNewswire Inc. • Kaplan Fox & Kilsheimer Llp

Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.

CAPR PNR BE class action lawsuit securities litigation FDA briefing documents statistical analysis plan investor losses

Sentiment note

Company faced significant regulatory scrutiny when FDA documents revealed undisclosed changes to statistical analysis plans for a drug application, leading to a severe 64% stock price decline and triggering a class action lawsuit for investor losses.

Negative Aug 26, 2026 • 02:05 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action lawsuit has been filed against Capricor Therapeutics for allegedly failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased securities between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.

CAPR class action lawsuit securities fraud FDA disclosure violations statistical analysis plan Deramiocel stock decline material information

Sentiment note

The company faces a class action lawsuit for failing to disclose material information about changes to its drug candidate's statistical analysis plan. The FDA found the modifications were made without prior review or approval, and the stock experienced a severe 64% decline following the disclosure of unfavorable benefit-risk profile findings.

Negative Aug 25, 2026 • 16:50 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Capricor Therapeutics faces a class action securities fraud lawsuit after the FDA criticized the company's statistical analysis methods for its Deramiocel cell therapy trial. The FDA's briefing documents questioned the scientific justification for data conversion methods and concluded the benefit-risk assessment was unfavorable. Following the FDA's concerns and an advisory committee's 9-3 vote against efficacy, Capricor's stock plummeted 62% on July 27, 2026. Investors who purchased shares between December 17, 2025 and July 26, 2026 can file lead plaintiff motions by September 28, 2026.

CAPR securities fraud class action lawsuit FDA approval clinical trial data Deramiocel Duchenne muscular dystrophy statistical analysis plan

Sentiment note

The company faces a securities fraud lawsuit for allegedly failing to disclose material facts about changes to clinical trial statistical analysis plans and FDA disagreement with those changes. The FDA's briefing documents criticized data integrity and analysis methods, leading to an unfavorable efficacy assessment. The stock declined 62% following FDA concerns, indicating severe loss of investor confidence and significant regulatory setback for the company's lead therapeutic candidate.

Negative Aug 25, 2026 • 13:31 UTC GlobeNewswire Inc. • Schall, Brown & Schwartz Llp

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for allegedly making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of non-approval. The class period spans December 17, 2025 to July 26, 2026, with a deadline of September 28, 2026 for investors to participate.

CAPR securities fraud class action lawsuit Deramiocel Biologics License Application FDA approval statistical analysis plan shareholder rights

Sentiment note

The company is accused of making false and misleading statements to the market, changing clinical trial analysis plans without FDA approval, and facing significant risk of BLA rejection. These allegations of fraud and regulatory non-compliance resulted in investor losses.

Negative Aug 25, 2026 • 12:00 UTC GlobeNewswire Inc. • Robbins Geller Rudman & Dowd Llp

INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit - CAPR

Robbins Geller Rudman & Dowd LLP announced class action lawsuits against Capricor Therapeutics, Wix.com Ltd., and Primoris Services Corporation for alleged securities fraud. The Capricor lawsuit alleges the company made false statements regarding changes to statistical analysis plans for its lead drug Deramiocel without FDA approval, resulting in a 64% stock price drop after FDA briefing documents revealed concerns about data integrity and efficacy. Investors have until specified deadlines in September 2026 to seek lead plaintiff appointments.

CAPR WIX PRIM class action lawsuit securities fraud FDA approval statistical analysis plan Deramiocel

Sentiment note

Company faces securities fraud allegations for allegedly making false statements about FDA approval of statistical analysis plan changes for its lead drug candidate. Stock declined 64% following FDA briefing documents revealing concerns about data integrity and efficacy, with an advisory committee voting against the drug's approval.

Negative Aug 24, 2026 • 23:10 UTC GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (CAPR) for allegedly making material misstatements regarding changes to its Deramiocel clinical trial statistical analysis plan and FDA compliance. The FDA revealed in July 2026 that Capricor failed to obtain FDA agreement on these changes prior to resubmitting its Biologics License Application, leading to FDA disagreement with the methodology and an unfavorable benefit-risk assessment. The stock fell 64% following the FDA's disclosure. Investors who purchased CAPR securities between December 17, 2025 and July 26, 2026 can seek lead plaintiff status by September 28, 2026.

CAPR securities fraud class action lawsuit FDA compliance statistical analysis plan Deramiocel Biologics License Application material misstatements

Sentiment note

The company is accused of making materially false statements about FDA compliance and clinical trial methodology. The FDA disagreed with the company's statistical analysis changes, deemed the benefit-risk assessment unfavorable, and the stock declined 64% on the news. This represents significant regulatory and financial setbacks.

Negative Aug 20, 2026 • 22:08 UTC The Motley Fool • Motley Fool Transcribing

Capricor (CAPR) Q2 2026 Earnings Call Transcript

Capricor Therapeutics reported Q2 2026 results with a net loss of $40.7 million ($0.70 per share) and cash reserves of $237.9 million. The company faced a significant setback when the FDA Advisory Committee voted 3-9 against approving Deramiocel for cardiomyopathy in DMD patients. However, management plans to submit a BLA amendment focusing on upper limb skeletal muscle function, supported by positive HOPE-3 primary endpoint data showing statistically significant slowing of disease progression (p=0.029). The company is scaling manufacturing capacity and pursuing arbitration with NS Pharma over distribution agreement disputes.

CAPR Deramiocel Duchenne muscular dystrophy FDA Advisory Committee BLA amendment upper limb function cardiomyopathy clinical trial

Sentiment note

The company experienced a major regulatory setback with a 9-3 negative Advisory Committee vote on its primary cardiomyopathy indication, despite positive primary endpoint data on upper limb function. While management is pursuing an alternative regulatory pathway, the company faces significant cash burn ($40.7M net loss in Q2), declining cash reserves (from $318.1M to $237.9M), and ongoing disputes with its distribution partner NS Pharma. The stock declined 14.35% following the announcement.